Drug intelligence / Profile preview

avanafil + amlodipine

Development stage
Unknown
Lead developer
VIVUS LLC
Modality
Small Molecules
Administration
Oral
01

Overview

Avanafil + amlodipine is a combination of two pharmaceutical drugs, each with distinct mechanisms of action and clinical uses. Avanafil is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males. It works by selectively inhibiting PDE5, leading to increased levels of cGMP in the corpus cavernosum during sexual stimulation, resulting in smooth muscle relaxation and enhanced blood flow to the penis[4][6][8]. Amlodipine is a dihydropyridine calcium channel blocker used primarily for treating high blood pressure (hypertension), angina (chest pain), and coronary artery disease. It acts as a peripheral arterial vasodilator by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle cells, thereby reducing peripheral vascular resistance and lowering blood pressure[1][2][7]. The combination may be considered when both indications—erectile dysfunction and hypertension or angina—are present; however, caution is advised due to potential additive effects on lowering blood pressure[3].

Brand names
Spedra
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on avanafil + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on avanafil + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call